Rifampin: Nursing Drug Guide, Hepatotoxicity & Drug Interactions
Healthcare medication guide: surveillance for rifampin hepatotoxicity on multidrug TB regimens, enzyme-induction interaction checks before every new medication, fasting oral administration, harmless orange body-fluid discoloration teaching, and non-hormonal contraception counseling.
Rifampin-associated liver injury ranges from asymptomatic transaminase elevations to fulminant hepatic failure and death — risk rises with pre-existing liver disease and concurrent hepatotoxic drugs such as isoniazid or halothane. Rifampin is also a potent CYP450 and transporter inducer that can sharply lower exposure to hormonal contraceptives, warfarin, HIV antivirals, immunosuppressants, and many other agents. Perform baseline hepatic enzymes, bilirubin, CBC, and creatinine in adults; monitor symptoms monthly and LFTs every 2–4 weeks when liver disease is present. Hold and notify the prescriber/pharmacist when hepatic injury is suspected.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm active TB is not on rifampin monotherapy, reconcile new prescriptions with pharmacy (rifampin induces metabolism of warfarin, oral contraceptives, HIV therapy, and dozens of other drugs), ask about anorexia, nausea, dark urine, or jaundice, and give oral rifampin on an empty stomach. Orange urine and tears are expected; yellow sclera plus rising AST/ALT means hold rifampin and contact the prescriber the same shift.
Most common brand names
Rifampin (rifampicin) is a cornerstone rifamycin for tuberculosis treatment and selected meningococcal carrier eradication.
Common U.S. brands include Rifadin and Rimactane. Capsules are supplied as 150 mg and 300 mg. Rifampin appears in multidrug tuberculosis protocols with isoniazid, pyrazinamide, and ethambutol per susceptibility and local formulary — verify whether combination products duplicate rifampin on the MAR.
Why we give it — Indications
Rifampin is bactericidal against Mycobacterium tuberculosis and indicated for all forms of drug-susceptible tuberculosis in combination with other effective agents. It is also used for short-course eradication of Neisseria meningitidis from the nasopharynx in asymptomatic carriers — not for treatment of active meningococcal disease.
| Use | Detail |
|---|---|
| Tuberculosis (combination therapy) | Initial short-course TB therapy commonly includes rifampin with isoniazid and pyrazinamide for about 2 months, then rifampin plus isoniazid for at least 4 months per CDC/ATS guidance. Adults: 10 mg/kg once daily, maximum 600 mg/day PO. |
| Meningococcal carrier state | Asymptomatic nasopharyngeal carriers: adults 600 mg twice daily for 2 days per labeling. Not indicated for treatment of invasive meningococcal infection because resistance emerges rapidly. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Rifampin inhibits DNA-dependent RNA polymerase in susceptible mycobacteria and certain gram-positive and gram-negative organisms. Resistance emerges rapidly with monotherapy — nurses must verify companion antituberculosis agents on every MAR pass. Rifampin potently induces CYP450 enzymes and drug transporters, accelerating clearance of many co-medications; this pharmacokinetic effect is the main reason nurses must flag new orders to pharmacy during rifampin therapy.
Dosing overview
Dosing depends on indication (TB vs meningococcal carrier), weight, and route. Confirm weight for mg/kg calculations and maximum 600 mg/day for daily TB dosing in adults.
Missed dose: Follow institutional tuberculosis DOT protocol. Labeling cautions against intentional or accidental interruption of daily rifampin because flu-like hypersensitivity and renal reactions have occurred when therapy was resumed. Do not double the next dose without prescriber or pharmacist guidance.
Before you give it — Safety check
Pretreatment checks
- Confirm active TB is on multidrug therapy — not rifampin alone — and verify susceptibility-directed companion drugs on the MAR.
- Baseline hepatic enzymes, bilirubin, serum creatinine, CBC, and platelet count in adults per labeling; review alcohol use and symptoms of liver injury.
- Perform medication reconciliation for interacting drugs (warfarin, hormonal contraceptives, HIV antivirals, immunosuppressants, anticonvulsants) and counsel on non-hormonal contraception.
Contraindications
- History of hypersensitivity to rifampin, any rifamycin, or formulation components.
- Concomitant ritonavir-boosted saquinavir (severe hepatocellular toxicity risk) and certain HIV protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir) due to loss of antiviral efficacy.
- Concomitant lurasidone or praziquantel per labeling; many other interacting drugs require avoidance or dose adjustment — consult pharmacy.
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Warfarin / oral anticoagulants | Rifampin decreases warfarin exposure — INR may fall below therapeutic range. | Notify pharmacy when rifampin starts or stops; monitor INR frequently per prescriber; teach bleeding and clot signs. |
| Hormonal contraceptives (estrogens/progestins) | Reduced contraceptive exposure — unintended pregnancy risk per labeling. | Teach alternative or backup non-hormonal contraception during rifampin and until metabolism normalizes after stop per prescriber. |
| Isoniazid and other hepatotoxic drugs | Increased hepatotoxicity potential when combined with isoniazid or halothane per warnings. | Monitor LFTs and prodromal symptoms closely; hold and escalate if liver injury suspected; avoid halothane concomitantly. |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral capsules (150 mg and 300 mg) are standard for tuberculosis and meningococcal carrier-state therapy. IV rifampin is indicated when oral therapy cannot be used per labeling. Give oral doses 1 hour before or 2 hours after a meal with a full glass of water — food reduces absorption by about 30%.
- Oral: once daily 1 hour before or 2 hours after meals with full glass of water; do not give with antacids within 1 hour.
- IV rifampin per institution protocol when patient cannot take oral therapy; oral switch requires prescriber order and absorption assessment.
- Document orange discoloration teaching, contraception counseling, and DOT observer when applicable.
Single-drug tuberculosis treatment leads to rapid resistance. Verify at least one additional active antituberculosis agent is ordered and available before administering rifampin for active disease.
Expected therapeutic response
- Gradual improvement in pulmonary symptoms (e.g., decreasing cough, improving energy) over weeks — not days.
- Negative or improving culture/smear data per laboratory protocol guides continuation (prescriber-led endpoint).
- Stable hepatic enzymes and absence of prodromal hepatitis symptoms on monthly review; carrier-state therapy clears nasopharyngeal carriage per microbiology follow-up.
Red flags — Stop and act
Distinguish expected orange discoloration of body fluids from pathologic jaundice. Prodromal hepatitis and severe hypersensitivity can progress quickly, especially on multidrug TB regimens.
- Anorexia, persistent nausea/vomiting, dark urine, scleral jaundice, or RUQ pain — hold rifampin and notify prescriber promptly
- Flu-like syndrome with fever, chills, hypotension, or shortness of breath — especially after interrupted dosing
- Purpura, unexplained bleeding, or INR/supratherapeutic anticoagulation changes after rifampin start or stop
- Severe rash with mucosal involvement, blistering, or systemic symptoms (suspected SJS/TEN/DRESS) — discontinue immediately
- Acute confusion, intractable vomiting, or orange secretions with lethargy after suspected overdose — emergency escalation and supportive care per toxicology protocol
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Hepatotoxicity (elevated transaminases, hepatitis, cholestasis, fulminant failure) | Reported from asymptomatic enzyme rise to death; higher with liver disease or other hepatotoxic drugs (e.g., isoniazid) | Hold rifampin; trend hepatic enzymes; notify prescriber same shift; do not restart without specialist plan |
| Orange/red discoloration of body fluids (urine, sweat, tears, saliva, teeth) | Very common; harmless but stains soft contact lenses permanently | Teach expected effect; distinguish from pathologic jaundice when sclera are yellow and LFTs rise |
| GI upset (nausea, vomiting, heartburn, diarrhea) | Reported in labeling | Supportive care; separate from antacids; distinguish prodromal hepatitis from benign GI upset |
| Hypersensitivity / flu-like syndrome | More common with intermittent or interrupted dosing; may include fever, chills, myalgias, hypotension | Stop drug; escalate per protocol; do not resume interrupted therapy without prescriber plan |
| Cutaneous reactions (rash, pruritus, SCAR including SJS/TEN/DRESS) | Reported; severe cutaneous reactions require immediate discontinuation | Hold rifampin at first significant rash with systemic symptoms; urgent escalation for mucosal involvement |
| Hematologic (thrombocytopenia, hemolytic anemia, coagulopathy) | Thrombocytopenia more often with high-dose intermittent therapy; vitamin K–dependent bleeding reported | Review CBC and coagulation studies; hold and notify for purpura, bleeding, or unexplained anemia |
| CNS (headache, drowsiness, confusion, ataxia) | Reported | Neurologic assessment; consider overdose if acute confusion with orange secretions |
On a small screen, swipe or scroll sideways to see the full table.
Specific incidence rates for individual adverse events are not specified in the reviewed FDA prescribing information.
Overdose, toxicity, and antidote
Early overdose signs may include nausea, vomiting, abdominal pain, pruritus, headache, increasing lethargy, and intense orange-red discoloration of skin and secretions. Severe hepatotoxicity, seizures, arrhythmias, and cardiac arrest have been reported in fatal cases. Nonfatal adult overdoses are reported at approximately 9–12 g; fatal ingestions at approximately 14–60 g per labeling.
Management principles (prescribing information)
- Antidote: No specific antidote is listed in the reviewed prescribing information.
- Supportive care: Secure airway, treat nausea/vomiting, gastric lavage within 2–3 hours when appropriate, activated charcoal, antiemetics, forced diuresis with measured intake and output.
- Severe cases: Extracorporeal hemodialysis or peritoneal dialysis with forced diuresis may be required per toxicology guidance.
- Monitor: Hepatic enzymes, bilirubin, mental status, and cardiac rhythm; alcohol co-ingestion increases risk per labeling reports.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Rifampin vs rifabutin vs rifapentine—all are rifamycins with different interaction and toxicity profiles; verify full drug name on MAR and pharmacy label
- 150 mg vs 300 mg capsules—independent double-check and barcode scan; confirm total daily milligrams match weight-based calculation (max 600 mg/day for TB)
- Fixed-dose combination products—distinguish rifampin monotherapy from isoniazid/rifampin or multidrug TB kits ordered separately
- TB vs meningococcal carrier dosing—carrier prophylaxis is 600 mg twice daily for two days in adults, not the same as daily TB therapy
- Intermittent high-dose error—doses >600 mg once or twice weekly increase flu-like and hematologic reactions per labeling; confirm DOT regimen with pharmacy
- Orange urine mistaken for bleeding—document expected discoloration teaching so benign rifampin effect is not confused with hematuria
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Timing | Give once daily 1 hour before or 2 hours after a meal with a full glass of water — food reduces absorption ~30% per labeling. |
| Antacids | Separate antacids by at least 1 hour before rifampin; probenecid and cotrimoxazole may increase rifampin levels — ask pharmacy. |
| DOT | Directly observed therapy is standard for intermittent TB regimens; document intentional interruption risks (flu-like syndrome, renal hypersensitivity on restart). |
| Contact lenses | Warn patients soft lenses may be permanently stained — use glasses during therapy if needed. |
| Lab timing | Perform LFTs and gallbladder contrast studies before the morning rifampin dose — therapeutic levels can alter standard assays per labeling. |
| Commonly missed | Contraception and warfarin interaction counseling; attributing orange tears to infection; giving with breakfast; missing monthly symptom review. |
| Ask pharmacy when | New HIV, transplant, anticoagulant, oral contraceptive, or anticonvulsant orders; suspected interaction; IV formulation or suspension compounding questions. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pre-existing liver disease / daily alcohol use | Fatal hepatic dysfunction reported — rifampin only if benefit outweighs risk with LFTs every 2–4 weeks and low threshold to discontinue. |
| Concurrent isoniazid or other hepatotoxic therapy | Enhanced hepatotoxicity monitoring required per labeling — same-shift hold for prodromal symptoms. |
| Pregnancy / postpartum / vitamin K deficiency states | Teratogenic in animals; use in pregnancy only if benefit justifies risk. Late-pregnancy exposure may cause maternal/infant postnatal hemorrhage — vitamin K may be indicated. Monitor coagulation in at-risk patients. |
| Pregnancy | Teratogenic in rodents (spina bifida, cleft palate) per labeling; no adequate controlled human studies — use during pregnancy only if potential benefit justifies fetal risk. Active TB during pregnancy should be treated because maternal benefit generally outweighs risk; rifampin plus isoniazid is a common regimen per guidelines. |
| Lactation | Low rifampin levels in breast milk are not expected to harm infants per LactMed; breastfeeding need not be discouraged, but milk may stain orange and levels are insufficient for infant TB treatment. Monitor infant for liver enzyme changes per specialist guidance. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Monthly symptom interview for hepatitis prodrome; baseline and periodic AST/ALT, bilirubin, CBC, platelets, and creatinine in adults per labeling.
- Trend liver function tests and basic metabolic panel components on multidrug TB protocols; INR when warfarin co-therapy present.
- Assess for flu-like syndrome, thrombocytopenia, hypersensitivity, and breakthrough infection signs when interacting drugs are co-prescribed; repeat Quantiferon or culture data are prescriber-led — nurses monitor treatment tolerance and adherence.
Document
- Indication (TB vs carrier), weight-based dose, DOT observer, companion antituberculosis drugs, and fasting administration timing.
- Monthly symptom review, LFT values, interaction counseling (contraception, warfarin), hold events, and prescriber notifications.
- Teaching on orange body fluids, contact lens staining, alcohol avoidance, and when to report prodromal hepatitis symptoms.
Patient teaching
- Take rifampin on an empty stomach (1 hour before or 2 hours after food) with a full glass of water unless your clinician advises otherwise.
- Urine, sweat, tears, and saliva may turn orange-red — this is expected and harmless, but soft contact lenses may stain permanently.
- Report immediately: loss of appetite, nausea, vomiting, dark urine, yellow eyes/skin, unusual bleeding, severe rash, shortness of breath, or flu-like illness.
- Rifampin can make hormonal birth control pills, patches, and implants less reliable — use a non-hormonal backup method during therapy and until your clinician confirms safety after stopping.
- Do not start or stop other medicines, including herbal products and alcohol, without medical advice — rifampin interacts with many drugs.
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Prodromal hepatitis symptoms or signs of hepatic damage (anorexia, nausea, vomiting, dark urine, jaundice, RUQ pain, rising transaminases).
- Hypersensitivity features (rash with fever, angioedema, bronchospasm, thrombocytopenia with purpura, flu-like syndrome with hypotension).
- Active tuberculosis order shows rifampin alone without companion antituberculosis drugs.
- Contraindicated interacting drug newly ordered without pharmacy clearance (e.g., ritonavir-boosted saquinavir, lurasidone).
- Suspected acute overdose with severe lethargy, intractable vomiting, or hepatic enlargement — hold and activate emergency/toxicology pathway.
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Rifampin nursing workflow pairs liver surveillance on long TB courses with proactive interaction management — treat every new MAR entry during rifampin therapy as a pharmacy review trigger.
1. Check-before-you-give protocol
- Right patient, indication (TB vs meningococcal carrier), dose (daily 600 mg vs carrier BID schedule), and route.
- Companion TB drug(s) due for active disease — not rifampin monotherapy.
- Ask about appetite, nausea, dark urine, jaundice, and alcohol use; review latest LFTs and INR if on warfarin.
- Confirm fasting timing, contraception counseling documented, and no new interacting drugs without pharmacy review.
2. High-alert and safety badge
Interaction-surveillance medicationRifampin is not an ISMP high-alert drug, but potent enzyme induction and hepatotoxicity require disciplined interaction checks comparable to narrow-index therapies.
3. Clinical workflow: hold and question rules
- Hold and clarify if subtherapeutic INR or pregnancy on hormonal contraception alone is identified after rifampin start.
- Do not resume interrupted rifampin without prescriber plan — labeling warns of flu-like and renal hypersensitivity on restart.
- Escalate same shift for prodromal hepatitis even when orange discoloration alone has been previously taught as benign.
4. Critical teach-back questions
- “What color change in your urine is expected, and what color change in your eyes is dangerous?” Orange urine/sweat is expected; yellow eyes (jaundice) with feeling sick needs urgent call to the clinic.
- “What should you do about birth control while on rifampin?” Use a non-hormonal backup method — pills/patches may not work reliably until the clinician says otherwise.
5. Care coordination
Infectious diseases / TB clinic: Regimen selection, susceptibility results, LTBI vs active disease duration, and hepatotoxicity rechallenge decisions.
Pharmacy: Interaction review for every new drug, warfarin/INR adjustment, contraception alternatives, and therapeutic drug monitoring when applicable.
🧠 Quick mental checklist
- Is active TB on multidrug therapy — not rifampin alone?
- Has pharmacy reviewed new medications started since rifampin began?
- Any prodromal hepatitis symptoms or alcohol use since the last visit?
- Is the patient taking rifampin fasting with water — not with breakfast or antacids?
- Was contraception / warfarin interaction counseling documented?
Rifampin NCLEX practice questions
Practice NCLEX-style clinical judgment practice for rifampin using a tabbed latent-TB case (MAR, labs, history, nursing notes), then work through priority action, interaction cue recognition, transaminase trend interpretation, matrix urgency sorting, contraception judgment, and cloze administration timing—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, History, and nursing note details for this case.
- Rifampin 600 mg PO daily — LTBI regimen with isoniazid — due 0700 (fasting)
- Isoniazid 300 mg PO daily — companion drug — due 0700
- Warfarin 5 mg PO daily — for prior DVT — given 2100 yesterday
- Ethinyl estradiol/norethindrone PO daily — contraceptive — on MAR
- Calcium carbonate antacid — patient took with rifampin yesterday per nursing note
- Baseline AST 32 U/L, ALT 28 U/L (ULN 40 U/L) — week 0
- Week 2: INR 2.4 (therapeutic); AST 38 U/L — therapy continued
- Week 4 (today): AST 148 U/L, ALT 132 U/L; INR 1.4; total bilirubin 1.9 mg/dL
- Quantiferon TB Gold positive at intake; chest imaging without active disease
- 29-year-old on rifampin + isoniazid for latent TB after occupational exposure
- Reports 1–2 alcoholic drinks on weekends — documented at start
- Prior DVT; sexually active; uses combined hormonal contraceptive
- Week-4 symptoms: anorexia, nausea, dark urine — began 3 days ago; orange tears noted (sclera clear)
- 0640: Patient asks whether orange urine means kidney bleeding
- 0645: States she did not use backup contraception after rifampin start — thought pill alone was enough
- 0650: INR drop to 1.4 flagged in morning lab batch — warfarin dose not yet reviewed
- 0655: Nurse reviewing MAR, labs, and history tabs before 0700 rifampin dose
Answer key & rationale
Frequently asked questions
What must nurses check before giving rifampin?
Confirm multidrug therapy for active TB (not rifampin alone), correct indication and dose, baseline and latest hepatic enzymes, alcohol use, prodromal hepatitis symptoms, fasting administration timing, and reconcile interacting drugs — especially warfarin, hormonal contraceptives, HIV therapy, and immunosuppressants — with pharmacy.
When should rifampin be held?
Hold for prodromal hepatitis or rising transaminases, hypersensitivity or severe rash, active TB orders missing companion drugs, contraindicated drug interactions, or suspected overdose. Notify prescriber and pharmacy the same shift.
What adverse effects matter most with rifampin?
Hepatotoxicity (including fulminant liver failure) is the highest-stakes toxicity, especially with liver disease or isoniazid. Potent CYP450 induction reduces efficacy of many co-medications. Orange body-fluid discoloration is common and benign; flu-like syndrome and thrombocytopenia occur more with interrupted or high intermittent doses.
What labs and vitals should be monitored on rifampin?
Adults need baseline hepatic enzymes, bilirubin, creatinine, CBC, and platelets; monthly symptom interviews; periodic LFTs when liver disease is present (every 2–4 weeks). Monitor INR when warfarin is co-prescribed and assess for bleeding, rash, and flu-like symptoms.
Why does rifampin turn urine orange, and does it affect birth control?
Harmless orange-red discoloration of urine, sweat, tears, and saliva is expected and may stain soft contact lenses. Scleral yellowing with systemic symptoms is not benign — report promptly. Rifampin reduces hormonal contraceptive exposure; patients need alternative or backup non-hormonal contraception during therapy per labeling.
References
-
U.S. National Library of Medicine. RIFAMPIN capsule — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0391f1e1-70d4-4b15-8b58-055bb6a385b8
-
Centers for Disease Control and Prevention. Treatment for Drug-Susceptible Tuberculosis Disease.https://www.cdc.gov/tb/hcp/treatment/tuberculosis-disease.html
-
Centers for Disease Control and Prevention. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers.https://www.cdc.gov/tb/hcp/treatment/latent-tuberculosis-infection.html
-
Nahid P, Dorman SE, et al. ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. CDC guideline PDF.https://www.cdc.gov/tb/publications/guidelines/pdf/Clin-Infect-Dis.-2016-Nahid-cid_ciw376.pdf
-
Drugs and Lactation Database (LactMed). Rifampin. Bethesda (MD): National Library of Medicine.https://www.ncbi.nlm.nih.gov/books/NBK501348/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.